The stability and disease specificity of tsRNAs in biofluids (e.g., plasma tRF-36-PJB7MNLE308HP1B in MS) and of secreted proteins like AIMP1 in NMOSD position them as promising non-invasive biomarkers (10, 67). This evidence concerns the gene AIMP1 and myeloid sarcoma.